MIRA Pharmaceuticals received a Nasdaq delisting notice on July 8, 2024, for failing to maintain the minimum $1.00 bid price requirement. The company has until January 6, 2025, to regain compliance by achieving a closing bid price above $1.00 for at least 10 consecutive business days. The company outlined several strategic initiatives including an upcoming IND submission for Ketamir-2 and planned clinical trials in Q1 2025.Concurrently, MIRA announced positive preclinical results for MIRA-55, its novel oral pharmaceutical marijuana analog being studied for anxiety and cognitive decline. The compound demonstrated enhanced efficacy over THC at CB1 and CB2 cannabinoid receptors, showing stronger anxiety reduction effects and improved stability across dosage ranges. The findings suggest a potentially safer profile for therapeutic use compared to THC.

MIRA Pharmaceuticals received a Nasdaq delisting notice on July 8, 2024, for failing to maintain the minimum $1.00 bid price requirement. The company has until January 6, 2025, to regain compliance by achieving a closing bid price above $1.00 for at least 10 consecutive business days. The company outlined several strategic initiatives including an upcoming IND submission for Ketamir-2 and planned clinical trials in Q1 2025.Concurrently, MIRA announced positive preclinical results for MIRA-55, its novel oral pharmaceutical marijuana analog being studied for anxiety and cognitive decline. The compound demonstrated enhanced efficacy over THC at CB1 and CB2 cannabinoid receptors, showing stronger anxiety reduction effects and improved stability across dosage ranges. The findings suggest a potentially safer profile for therapeutic use compared to THC.